ES2134199T3 - Acido glutamico-descarboxilasa clonada. - Google Patents

Acido glutamico-descarboxilasa clonada.

Info

Publication number
ES2134199T3
ES2134199T3 ES91919674T ES91919674T ES2134199T3 ES 2134199 T3 ES2134199 T3 ES 2134199T3 ES 91919674 T ES91919674 T ES 91919674T ES 91919674 T ES91919674 T ES 91919674T ES 2134199 T3 ES2134199 T3 ES 2134199T3
Authority
ES
Spain
Prior art keywords
sub
gad
provides
decarboxylase
cloned
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91919674T
Other languages
English (en)
Inventor
Allan J Tobin
Mark G Erlander
Daniel L Kaufman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24346149&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2134199(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of ES2134199T3 publication Critical patent/ES2134199T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)

Abstract

MOLECULAS DE CADN QUE CODIFICAN POLIPEPTIDOS DE LA GAD SUB 65. LA INVENCION PRESENTA MOLECULAS DE CADN QUE CONTIENEN UNA PARTE DE LA SECUENCIA DE CADN DE LA GAD SUB 65 QUE CODIFICAN AL MENOS UN EPITOPE PARA AUTOANTICUERPOS DE LA GAD SUB 65. LA INVENCION PRESENTA TAMBIEN ELEMENTOS DE CLONACION CAPACES DE REPLICA Y EXPRESION QUE CONTIENEN MOLECULAS DE CADN QUE CODIFICAN LA GAD SUB 65. LA INVENCION PRESENTA ADEMAS HUESPEDES TRANSFORMADOS EN UN ELEMENTO QUE TIENE UNA MOLECULA DE CADN QUE CODIFICA LA GAD SUB 65. EN OTRA PUESTA EN PRACTICA DE LA INVENCION, LA INVENCION PREVE LA DETECCION DE AUTOANTICUERPOS CONTRA LA GAD SUB 65 UTILIZANDO LOS POLIPEPTIDOS DE LA GAD SUB 65 CODIFICADOS POR LAS MOLECULAS DE CADN DE LA INVENCION.
ES91919674T 1990-09-21 1991-09-23 Acido glutamico-descarboxilasa clonada. Expired - Lifetime ES2134199T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/586,536 US6682906B1 (en) 1990-09-21 1990-09-21 Cloned glutamic acid decarboxylase

Publications (1)

Publication Number Publication Date
ES2134199T3 true ES2134199T3 (es) 1999-10-01

Family

ID=24346149

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91919674T Expired - Lifetime ES2134199T3 (es) 1990-09-21 1991-09-23 Acido glutamico-descarboxilasa clonada.

Country Status (11)

Country Link
US (3) US6682906B1 (es)
EP (1) EP0502188B1 (es)
JP (3) JPH05503220A (es)
KR (1) KR100220277B1 (es)
AT (1) ATE181962T1 (es)
CA (1) CA2040555C (es)
DE (1) DE69131419T2 (es)
DK (1) DK0502188T3 (es)
ES (1) ES2134199T3 (es)
GR (1) GR3031082T3 (es)
WO (1) WO1992005446A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004632A1 (en) * 1990-09-07 1992-03-19 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US6682906B1 (en) 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
EP0572478B1 (en) 1991-02-22 2005-09-07 The Walter And Eliza Hall Institute Of Medical Research Hbgad and higad polypeptides and nucleic acids and their use for the diagnosis and treatment of gad autoantigen associated diseases
AU1749692A (en) * 1991-05-03 1992-12-21 Novo Nordisk A/S Islet cell autoantigen (gad) for the detection of preclinical diabetes
IL101872A0 (en) * 1991-05-15 1992-12-30 Univ Washington Cloning and expression of human islet glutamic acid decarboxylase autoantigen
DE4237244A1 (de) * 1992-11-04 1994-05-05 Elias Entwicklungslabor Fuer I Verfahren zur Herstellung hochreiner humaner GAD-1- und GAD-2- Proteine
EP0701569B1 (en) * 1992-12-03 2008-11-12 The Regents Of The University Of California Improved reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome
TW305936B (es) * 1993-02-09 1997-05-21 Univ Monash
GB9319429D0 (en) 1993-09-21 1993-11-03 London Health Ass Methods and products for controlling immune responses in mammals
CN1112933A (zh) 1994-01-20 1995-12-06 伯伦格·曼海姆有限公司 抗原特异性活化t淋巴细胞，其检测和用途
FR2726575B1 (fr) * 1994-11-09 1996-12-20 Rhone Poulenc Rorer Sa Virus recombinants, preparation et utilisation en therapie genique
IL113052A0 (en) * 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
FR2717823B1 (fr) * 1994-03-23 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
SE9401118L (sv) * 1994-03-31 1995-10-01 Synectics Medical Ab GAD, en metod för framställning av modifierat GAD samt en metod för att tillföra modifierat GAD samt peptid
DE4418223A1 (de) 1994-05-25 1995-11-30 Boehringer Mannheim Gmbh Verfahren zum Nachweis des Vorliegens eines Insulin-abhängigen Diabetes mellitus
US5561049A (en) * 1994-09-21 1996-10-01 Behringwerke Ag Method for detecting antibodies
ATE364701T1 (de) 1995-02-20 2007-07-15 Inst Medical W & E Hall Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren
SE9503379D0 (sv) * 1995-09-29 1995-09-29 Synectics Medical Ab A modified GAD, a method for producing a modified GAD, a method for supplying a modified GAD, a peptide and the use of an ordinary and/or a modified GAD
WO1997017450A2 (en) * 1995-11-09 1997-05-15 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in pichia methanolica
US6093396A (en) * 1996-09-27 2000-07-25 Diamyd Therapeutics Ab Modified glutamic acid decarboxylase (GAD)
EP1793000A1 (en) * 1997-02-25 2007-06-06 GTC Biotherapeutics, Inc. Transgenically produced non-secreted proteins
US6528699B1 (en) 1997-02-25 2003-03-04 Genzyme Transgenics Corporation Transgenically produced non-secreted proteins
US6303325B1 (en) 1998-05-29 2001-10-16 Dade Behring Inc. Method for detecting analytes
AU3958999A (en) * 1999-06-01 2000-12-18 Kyokuto Pharmaceutical Industrial Co., Ltd. Method for assaying anti-gad antibody and kit
WO2001089583A2 (en) * 2000-05-23 2001-11-29 Neurologix, Inc. Glutamic acid decarboxylase (gad)_delivery system for treating neurodegenerative diseases
US7695959B2 (en) * 2000-05-23 2010-04-13 Neurologix, Inc. Glutamic acid decarboxylase (GAD) based delivery systems
AU2003300681A1 (en) * 2002-10-02 2004-05-04 Diamyd Medical Ab Formulation of glutarmic acid decarboxylase (gad65) and serum albumin
EP1865063A1 (en) * 2005-03-15 2007-12-12 Tokyo University of Science, Educational Foundation Glutamate decarboxylase mutant
CN105936887A (zh) 2007-03-16 2016-09-14 基因组股份公司 用于1,4-丁二醇和其前体生物合成的组合物和方法
KR20100022022A (ko) * 2007-04-24 2010-02-26 다이아미드 쎄라퓨틱스 아베 자가면역 질환 및 암을 치료하기 위한 의약 및 방법
US7947483B2 (en) 2007-08-10 2011-05-24 Genomatica, Inc. Methods and organisms for the growth-coupled production of 1,4-butanediol
JP5912529B2 (ja) 2008-09-10 2016-04-27 ゲノマチカ， インク． １，４−ブタンジオールの生成のための微生物体
EP3199511B1 (en) * 2009-06-04 2020-01-29 Genomatica, Inc. Process of separating components of a fermentation broth
CN102498215A (zh) 2009-06-04 2012-06-13 基因组股份公司 生产1,4-丁二醇的微生物和相关方法
JP2013507145A (ja) * 2009-10-13 2013-03-04 ゲノマチカ， インク． １，４−ブタンジオール、４−ヒドロキシブタナール、４−ヒドロキシブチリル−ＣｏＡ、プトレシン及び関連化合物の生成のための微生物体並びに関連する方法
US8530210B2 (en) * 2009-11-25 2013-09-10 Genomatica, Inc. Microorganisms and methods for the coproduction 1,4-butanediol and gamma-butyrolactone
US8445244B2 (en) * 2010-02-23 2013-05-21 Genomatica, Inc. Methods for increasing product yields
US8048661B2 (en) * 2010-02-23 2011-11-01 Genomatica, Inc. Microbial organisms comprising exogenous nucleic acids encoding reductive TCA pathway enzymes
EP2855687B1 (en) 2012-06-04 2020-04-22 Genomatica, Inc. Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4487830A (en) 1982-05-14 1984-12-11 American Hoechst Corporation Enzyme/immunofluorescent assay for autoantibodies
US4751181A (en) 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
EP0448635B1 (en) 1988-12-13 1995-09-20 University Of Florida Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5645998A (en) * 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
NO306996B1 (no) 1989-02-17 2000-01-24 Bayer Ag Isolert bukspyttkjerteloey-celle-(ICA)-antigen for in vitro- bruk
ATE144326T1 (de) * 1990-08-17 1996-11-15 Univ Florida Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes
WO1992004632A1 (en) * 1990-09-07 1992-03-19 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US5512447A (en) * 1990-09-07 1996-04-30 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US5998366A (en) * 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
US6682906B1 (en) 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5475086A (en) * 1990-09-21 1995-12-12 The Regents Of The University Of California Cloned glutamic acid decarboxylase peptides
EP0572478B1 (en) * 1991-02-22 2005-09-07 The Walter And Eliza Hall Institute Of Medical Research Hbgad and higad polypeptides and nucleic acids and their use for the diagnosis and treatment of gad autoantigen associated diseases
IL101872A0 (en) * 1991-05-15 1992-12-30 Univ Washington Cloning and expression of human islet glutamic acid decarboxylase autoantigen

Also Published As

Publication number Publication date
CA2040555C (en) 2003-11-04
EP0502188A4 (en) 1994-05-18
KR100220277B1 (ko) 1999-09-15
US20050164342A1 (en) 2005-07-28
US6277586B1 (en) 2001-08-21
CA2040555A1 (en) 1992-03-22
EP0502188B1 (en) 1999-07-07
JP2007236390A (ja) 2007-09-20
AU657501B2 (en) 1995-03-16
AU8877191A (en) 1992-04-15
WO1992005446A1 (en) 1992-04-02
GR3031082T3 (en) 1999-12-31
US6682906B1 (en) 2004-01-27
JPH05503220A (ja) 1993-06-03
EP0502188A1 (en) 1992-09-09
ATE181962T1 (de) 1999-07-15
US7329511B2 (en) 2008-02-12
KR920702233A (ko) 1992-09-03
DK0502188T3 (da) 2000-01-24
JP2000333671A (ja) 2000-12-05
DE69131419T2 (de) 2000-03-30
DE69131419D1 (de) 1999-08-12

Similar Documents

Publication Publication Date Title
ES2134199T3 (es) Acido glutamico-descarboxilasa clonada.
PT765394E (pt) Lacases myceliophthora purificadas e acidos nucleicos que as codificam
ES2153037T3 (es) Lacasas purificadas de scytalidium y acidos nucleicos que las codifican.
HK1013847A1 (en) Gdf-1 and uog-1 proteins
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
DK0994728T3 (da) Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf
IT1278478B1 (it) Dispositivo antifurto per veicoli con la codificazione elettronica dell'autorizzazione all'uso.
ITRM950198A0 (it) Dispositivo antifurto per veicoli con codificazione elettronica dell'autorizzazione all'uso.
DE69014440D1 (de) Sprachcodierungs-/-decodierungssystem.
ITRM950197A0 (it) Dispositivo antifurto per veicoli con codificazione elettronica dell'autorizzazione all'uso.
PT1346034E (pt) Polipéptido da protease de clivagem do factor de von willebrand (vwf), ácido nucleico que codifica o polipéptido e utilização do polipéptido
ATE271129T1 (de) Isoliertes p27 protein und nukleinsäure dafür kodierend
ES2152251T3 (es) Variantes del dominio lectina de la selectina.
IL115792A0 (en) Al-1 neurothophic factor
WO1997041234A3 (en) PROTEINS INVOLVED IN THE SYNTHESIS AND ASSEMBLY OF O-ANTIGEN IN $i(PSEUDOMONAS AERUGINOSA)
ATE527358T1 (de) Ribosomen inaktivierendes protein vom typ-1
MXPA00002111A (es) Biomoleculas que contienen un peptido elastomerico.
ES538000A0 (es) Un procedimiento para obtener un adn que codifica un factor de necrosis de tumor de conejo
DK0724637T4 (da) Kortikotropinfrigørende faktor2-receptorer
WO1994003601A8 (en) Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
DE69840326D1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
SE9602822D0 (sv) New receptor
EP1251176A3 (en) Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide
ES2165996T3 (es) Poliacrilamida con bajo peso molecular.
CA2049037A1 (en) Aqueous resin preparations and a process for stabilizing rock and plugging cavities

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 502188

Country of ref document: ES